Septerna
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
250 E Grand Ave, South San Francisco, Ca...Phone Number
(650) 338-3533Website
www.septerna.comRevenue
$72.3 MillionStock Symbol
SEPNIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Septerna
Based in South San Francisco, CA, Septerna is a clinical-stage biotechnology company focused on developing new therapies targeting GPCRs. Using its proprietary Native Complex Platform, the company is advancing a pipeline of oral small-molecule drug candidates in areas such as endocrinology, immunology, inflammation, and metabolic diseases, both independently and with partners.Explore more
Septerna Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Septerna your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Septerna has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Septerna
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Septerna had a recent Job posting/layoffs
Product Launch: Get notified when Septerna launches new products
Funding: Get notified immidiatlly once Septerna has new funding data
Septerna, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Septerna is spiking on competitors!
Earning: See what the market has to say on Septerna recently announced quarterly report
Recommended Actions
Find VP level buyers at Septerna
Find more new buyers
Compare Similar Companies to Septerna
Compare insights from companies similar to Septerna, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Septerna is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Septerna is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Septerna.
Septerna financials insights
Gather financial insights about Septerna, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$100M
2023
Series B
$150M
2024
Stock Offering
$288M
Septerna Tech Stack
A closer look at the technologies used by Septerna
Most Recent Scoops
Project
Septerna has announced positive Phase I clinical results for SEP-631, the company's oral small molecule MRGPRX2 negative allosteric modulator for mast cell-driven diseases, demonstrating that the therapy was well-tolerated, supported once-daily oral dosing pharmacokinetics, and provided clinical proof of mechanism through robust inhibition of codeine-induced skin wheal formation across dosage ranges of 10 mg to 200 mg once daily.
Pharmaceuticals, Clinical Operations
Earnings
reported a cash position of $522 million on the balance sheet as of March 31, 2026, providing the company with a cash runway of at least into 2029.
Accounting, Financial Reporting, Business Finance, Finance
Project
Septerna has initiated a Phase I clinical trial for SEP-479, the company's next-generation oral small molecule PTH receptor agonist candidate for hyperparathyroidism, with dosing currently underway in healthy adult volunteers. Data from this study is anticipated in late 2026 or early 2027.
Pharmaceuticals, Clinical Operations
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Events, Medical Research, Pharmaceuticals, Clinical Operations
Septerna News & Media
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
This clinical-stage biotech focused on GPCR-targeted therapies reported a notable insider sale amid rapid share price appreciation.Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Septerna, Inc. (SEPN) Bank of America Global Healthcare Conference 2026 May 12, 2026 8:01 PM EDTCompany ParticipantsJeffrey Finer - Co-Founder, CEO &...Septerna to Present at Bank of America Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the Bank of America Securities Health Care Conference on Tuesday, May 12, 2026, at 5:00 p.m. PT in Las Vegas.Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Septerna
Sign Up For FreeTo access detailed company insights
Based in South San Francisco, CA, Septerna is a clinical-stage biotechnology company focused on developing new therapies targeting GPCRs. Using its proprietary Native Complex Platform, the company is advancing a pipeline of oral small-molecule drug candidates in areas such as endocrinology, immunology, inflammation, and metabolic diseases, both ind... Read More
